a drug for schizophrenia

Abstract

The invention relates to a medicine for treating schizophrenia. The medicine is prepared from the following crude drugs and pharmaceutically acceptable carriers in parts by weight: 80 parts of pleurotus albellus, 70 parts of musella lasiocarpa, 70 parts of ardisia crispa, 60 parts of chrysopogon aciculatus, 60 parts of botrychiam ternatum, 50 parts of fraxinus malacophylla, 50 parts of herb of nepal pennywort, 50 parts of medical angiopteris rhizome, 50 parts of styrax obassia, 50 parts of seeds of gram chickpea, 30 parts of Iran speedwell herb and 20 parts of heliotropium indicum. The clinical application shows that the medicine for treating schizophrenia has the advantages of rapid effect taking, remarkable treatment effect, good tolerance, low cost and no toxic or side effect.

Description

technical field

[0001] The invention relates to the field of medicine, in particular to a medicine for treating schizophrenia. Background technique

[0002] Schizophrenia is an epidemic disease characterized by abnormal mental activity due to brain dysfunction. It is the most complicated of all mental diseases and is a serious, chronic, and disabling disease of the brain. What was once considered a mental illness is now classified as a brain disorder. Schizophrenia is a common clinical psychiatric disease whose etiology has not been fully elucidated. The clinical manifestations are disturbances in perception, thinking, emotion, behavior, etc., as well as incoordination between mental activities and the environment. The disease can occur in multiple age groups, especially in young and middle-aged people. The course of the disease is often protracted and progresses slowly. It often gradually aggravates or worsens due to inactive treatment or no effective drug treatment, and e...